Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model

Toxicological Sciences

Volumn 136, Issue 2, 2013, Pages 581-594

  Guo, Liang ^a,g   Coyle, Luke ^g   Abrams, Rory M C ^b,g   Kemper, Raymond ^c,g   Chiao, Eric T ^d,g   Kolaja, Kyle L ^e,f,g  

^a FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d BIOGEN   (United States)

^e Cellular Dynamics International   (United States)

^f To whom correspondence should be addressed at Cellular Dynamics International   (United States)

^g HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; DILTIAZEM; DOXORUBICIN; GELDANAMYCIN; ION CHANNEL; NIFEDIPINE; NITRENDIPINE; OUABAIN; PENTAMIDINE; POTASSIUM CHANNEL HERG; SOTALOL; SUNITINIB; VERAPAMIL;

ALGORITHM; ARRHYTHMOGENESIS; ARTICLE; CARDIOTOXICITY; CARDIOVASCULAR RISK; CONTROLLED STUDY; CYTOTOXICITY; DRUG INDUCED ARRHYTHMIA; ECG ABNORMALITY; ELECTRIC ACTIVITY; HEART ARRHYTHMIA; HEART BEAT; HEART RHYTHM; HUMAN; HUMAN INDUCED PLURIPOTENT STEM CELL DERIVED CARDIOMYOCYTE; IMPEDANCE CARDIOGRAPH; IN VITRO STUDY; IN VIVO STUDY; PLURIPOTENT STEM CELL; QT PROLONGATION; RISK ASSESSMENT; TORSADE DES POINTES;

ARRHYTHMIA; CARDIOMYOCYTES; CARDIOTOXICITY; INVESTIGATIVE TOXICOLOGY.; LABEL-FREE TECHNOLOGY; STEM CELLS;

ARRHYTHMIAS, CARDIAC; CELLS, CULTURED; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MODELS, THEORETICAL; MYOCYTES, CARDIAC; RISK ASSESSMENT;

EID: 84890320017     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kft205     Document Type: Article

References (39)

1. Abassi, Y. A., Xi, B., Li, N., Ouyang, W., Seiler, A., Watzele, M., Kettenhofen, R., Bohlen, H., Ehlich, A., Kolossov, E., et al. (2012). Dynamic monitoring of beating periodicity of stem cell-derived cardiomyocytes as a predictive tool for preclinical safety assessment. Br. J. Pharmacol. 165, 1424-1441.
2. Babiarz, J. E., Ravon, M., Sridhar, S., Ravindran, P., Swanson, B., Bitter, H., Weiser, T., Chiao, E., Certa, U., and Kolaja, K. L. (2012). Determination of the human cardiomyocyte mRNA and miRNA differentiation network by fine-scale profiling. Stem Cells Dev. 21, 1956-1965.
3. Bagnes, C., Panchuk, P. N., and Recondo, G. (2010). Antineoplastic chemotherapy induced QTc prolongation. Curr. Drug Saf. 5, 93-96.
4. Chi, K. R. (2013). Revolution dawning in cardiotoxicity testing. Nat. Rev. Drug Discov. 12, 565-567.
5. Cohen, J. D., Babiarz, J. E., Abrams, R. M., Guo, L., Kameoka, S., Chiao, E., Taunton, J., and Kolaja, K. L. (2011). Use of human stem cell derived cardiomyocytes to examine sunitinib mediated cardiotoxicity and electrophysiological alterations. Toxicol. Appl. Pharmacol. 257, 74-83.
6. Dennis, A., Wang, L., Wan, X., and Ficker, E. (2007). hERG channel trafficking: Novel targets in drug-induced long QT syndrome. Biochem. Soc. Trans. 35(Pt 5), 1060-1063.
7. Ducroq, J., Moha ou Maati, H., Guilbot, S., Dilly, S., Laemmel, E., Pons- Himbert, C., Faivre, J. F., Bois, P., Stücker, O., and Le Grand, M. (2010). Dexrazoxane protects the heart from acute doxorubicin-induced QT prolongation: A key role for I(Ks). Br. J. Pharmacol. 159, 93-101.
8. Guengerich, F. P. (2011). Mechanisms of drug toxicity and relevance to pharmaceutical development. Drug Metab. Pharmacokinet. 26, 3-14.
9. Guo, L., Abrams, R. M., Babiarz, J. E., Cohen, J. D., Kameoka, S., Sanders, M. J., Chiao, E., and Kolaja, K. L. (2011). Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol. Sci. 123, 281-289.
10. Guo, L., and Guthrie, H. (2005). Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation. J. Pharmacol. Toxicol. Methods 52, 123-135.
11. Hamid, R., Rotshteyn, Y., Rabadi, L., Parikh, R., and Bullock, P. (2004). Comparison of alamar blue and MTT assays for high through-put screening. Toxicol. In Vitro 18, 703-710.
12. Hoffmann, P., and Warner, B. (2006). Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis?. A review of emerging trends. J. Pharmacol. Toxicol. Methods 53, 87-105.
13. Jonsson, M. K., Wang, Q. D., and Becker, B. (2011). Impedance-based detection of beating rhythm and proarrhythmic effects of compounds on stem cellderived cardiomyocytes. Assay Drug Dev. Technol. 9, 589-599.
14. Kattman, S. J., Koonce, C. H., Swanson, B. J., and Anson, B. D. (2011). Stem cells and their derivatives: A renaissance in cardiovascular translational research. J. Cardiovasc. Transl. Res. 4, 66-72.
15. Khan, J. M., Lyon, A. R., and Harding, S. E. (2013). The case for induced pluripotent stem cell-derived cardiomyocytes in pharmacological screening. Br. J. Pharmacol. 169, 304-317.
16. Kuryshev, Y. A., Ficker, E., Wang, L., Hawryluk, P., Dennis, A. T., Wible, B. A., Brown, A. M., Kang, J., Chen, X. L., Sawamura, K., et al. (2005). Pentamidine-induced long QT syndrome and block of hERG trafficking. J. Pharmacol. Exp. Ther. 312, 316-323.
17. Laverty, H., Benson, C., Cartwright, E., Cross, M., Garland, C., Hammond, T., Holloway, C., McMahon, N., Milligan, J., Park, B., et al. (2011). How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines? Br. J. Pharmacol. 163, 675-693.
18. Lu, H. R., Vlaminckx, E., Hermans, A. N., Rohrbacher, J., Van Ammel, K., Towart, R., Pugsley, M., and Gallacher, D. J. (2008). Predicting drug-induced changes in QT interval and arrhythmias: QT-shortening drugs point to gaps in the ICHS7B Guidelines. Br. J. Pharmacol. 154, 1427-1438.
19. Ma, J., Guo, L., Fiene, S. J., Anson, B. D., Thomson, J. A., Kamp, T. J., Kolaja, K. L., Swanson, B. J., and January, C. T. (2011). High purity human-induced pluripotent stem cell-derived cardiomyocytes: Electrophysiological properties of action potentials and ionic currents. Am. J. Physiol. Heart Circ. Physiol. 301, H2006-H2017.
20. Mirams, G. R., Cui, Y., Sher, A., Fink, M., Cooper, J., Heath, B. M., McMahon, N. C., Gavaghan, D. J., and Noble, D. (2011). Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk. Cardiovasc. Res. 91, 53-61.
21. Misner, D. L., Frantz, C., Guo, L., Gralinski, M. R., Senese, P. B., Ly, J., Albassam, M., and Kolaja, K. L. (2012). Investigation of mechanism of drug-induced cardiac injury and torsades de pointes in cynomolgus monkeys. Br. J. Pharmacol. 165, 2771-2786.
22. Nakamae, H., Tsumura, K., Hino, M., Hayashi, T., and Tatsumi, N. (2000). QT dispersion as a predictor of acute heart failure after high-dose cyclophosphamide. Lancet 355, 805-806.
23. Natarajan, A., Stancescu, M., Dhir, V., Armstrong, C., Sommerhage, F., Hickman, J. J., and Molnar, P. (2011). Patterned cardiomyocytes on microelectrode arrays as a functional, high information content drug screening platform. Biomaterials 32, 4267-4274.
24. Nguemo, F., Šaric, T., Pfannkuche, K., Watzele, M., Reppel, M., and Hescheler, J. (2012). In vitro model for assessing arrhythmogenic properties of drugs based on high-resolution impedance measurements. Cell. Physiol. Biochem. 29, 819-832.
25. O'Brien, P. J., Irwin, W., Diaz, D., Howard-Cofield, E., Krejsa, C. M., Slaughter, M. R., Gao, B., Kaludercic, N., Angeline, A., Bernardi, P., et al. (2006). High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch. Toxicol. 80, 580-604.
26. Peng, S., Lacerda, A. E., Kirsch, G. E., Brown, A. M., and Bruening-Wright, A. (2010). The action potential and comparative pharmacology of stem cellderived human cardiomyocytes. J. Pharmacol. Toxicol. Methods 61, 277-286.
27. Peters, M. F., Scott, C. W., Ochalski, R., and Dragan, Y. P. (2012). Evaluation of cellular impedance measures of cardiomyocyte cultures for drug screening applications. Assay Drug Dev. Technol. 10, 525-532.
28. Prystowsky, E. N. (1992). Effects of bepridil on cardiac electrophysiologic properties. Am. J. Cardiol. 69, 63D-67D.
29. Redfern, W. S., Carlsson, L., Davis, A. S., Lynch, W. G., MacKenzie, I., Palethorpe, S., Siegl, P. K., Strang, I., Sullivan, A. T., Wallis, R., et al. (2003). Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovasc. Res. 58, 32-45.
30. Saif, M. W., Shah, M. M., and Shah, A. R. (2009). Fluoropyrimidine-associated cardiotoxicity: Revisited. Expert Opin. Drug Saf. 8, 191-202.
31. Senkus, E., and Jassem, J. (2011). Cardiovascular effects of systemic cancer treatment. Cancer Treat. Rev. 37, 300-311.
32. Shah, N. R., Shah, A., and Rather, A. (2012). Ventricular fibrillation as a likely consequence of capecitabine-induced coronary vasospasm. J. Oncol. Pharm. Pract. 18, 132-135.
33. Shaikh, A. Y., and Shih, J. A. (2012). Chemotherapy-induced cardiotoxicity. Curr. Heart Fail. Rep. 9, 117-127.
34. Slordal, L., and Spigset, O. (2006). Heart failure induced by non-cardiac drugs. Drug Saf. 29, 567-586.
35. Svoboda, M., Poprach, A., Dobes, S., Kiss, I., and Vyzula, R. (2012). Cardiac toxicity of targeted therapies used in the treatment for solid tumours: A review. Cardiovasc. Toxicol. 12, 191-207.
36. Wang, L., Wible, B. A., Wan, X., and Ficker, E. (2007). Cardiac glycosides as novel inhibitors of human ether-a-go-go-related gene channel trafficking. J. Pharmacol. Exp. Ther. 320, 525-534.
37. Wu, X., Sun, Z., Meininger, G. A., and Muthuchamy, M. (2012). Application of atomic force microscopy measurements on cardiovascular cells. Methods Mol. Biol. 843, 229-244.
38. Xing, J. Z., Zhu, L., Gabos, S., and Xie, L. (2006). Microelectronic cell sensor assay for detection of cytotoxicity and prediction of acute toxicity. Toxicol. In Vitro 20, 995-1004.
39. Xu, J. J., Henstock, P. V., Dunn, M. C., Smith, A. R., Chabot, J. R., and de Graaf, D. (2008). Cellular imaging predictions of clinical drug-induced liver injury. Toxicol. Sci. 105, 97-105.